RT Journal Article
SR Electronic
T1 Rapid implementation of cross-sectional study: Post-acute sequelae of SARS-CoV-2 (PASC) in a racially and ethnically diverse sample in Illinois
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.29.21256304
DO 10.1101/2021.04.29.21256304
A1 Robin J. Mermelstein
A1 Meenakshy Aiyer
A1 Christine Canfield
A1 David Chestek
A1 Judith A. Cook
A1 Marina Del Rios
A1 Kathleen R. Diviak
A1 Angela M. Ellison
A1 Howard S. Gordon
A1 Sai Dheeraj Illendula
A1 Manasa Kandula
A1 Jonathan D. Klein
A1 Karen Larimer
A1 James Lash
A1 Janet Lin
A1 Jeffrey A. Loeb
A1 Teresa J. Lynch
A1 Hugh Musick
A1 Richard M. Novak
A1 Heather M. Prendergast
A1 Jerry A. Krishnan
YR 2021
UL http://medrxiv.org/content/early/2021/05/02/2021.04.29.21256304.abstract
AB Little is known about the pattern and course of recovery following acute COVID-19. Increasing numbers of reports describe persistent illness following infection with SARS-COV-2, also known as Post-Acute Sequelae of SARS-CoV-2 (PASC). This report describes the methods and results of a multi-pronged strategy to rapidly identify and enroll, over a one week period in April 2021, a racially and ethnically diverse sample of individuals and to characterize PASC among a this diverse sample. Participants were recruited through community outreach, clinical registries, and research registries across four cities in Illinois to complete an online survey. We examined presence of symptoms among 246 individuals who were at least three months past testing positive for SARS-CoV-2. Respondents were 70% female; 48% Hispanic/Latinx; 18% Black, and 28% White. Most had mild illness (78% were not hospitalized), and 26% reported they had not yet returned to their usual health within 3 months of their diagnosis. The most prevalent symptoms persisting 3-months following COVID-19 diagnosis included fatigue (20%), difficulty thinking (19%), problems with taste or smell (15%), and muscle or body aches (15%). In a multivariable logistic regression model, older age (40-59 vs. 18-39 years: adjusted odds ratio [aOR] = 0.46 [95% confidence interval, 0.24 to 0.90]) and having been hospitalized with COVID-19 (vs. not hospitalized: aOR = 0.28 [0.12 to 0.64]) were independently associated with a lower likelihood of recovery within 3 months. Compromised health continued well beyond the acute phase of COVID-19 in our ethnically diverse sample, especially among older individuals and those who were hospitalized. The partnerships with community- and faith-based organizations developed for the current study offer the potential to broadly disseminate study findings and to further understand and mitigate underlying determinants of risk, severity, and duration of PASC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work presented was funded in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The work was also supported in part with resources and the use of facilities at the Jesse Brown VA Medical Center, Chicago, Illinois. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veterans Affairs. None of the authors or institutions at any time received payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards at the University of Illinois Chicago (Protocol # 2021-0410) and Peoria (Protocol #1745454-1), Carle Hospital in Urbana (Protocol #21CRU3374), and Jesse Brown VA Medical Center (Protocol #162103-1) reviewed the ILLInet-PASC study protocol and determined the study to be exempt from on-going review because the data were de-identified at the time of collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available through the corresponding author